{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:23Z","timestamp":1793998043472,"version":"4.8.0"},"reference-count":72,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic myeloid leukemia (CML) represents a paradigm of success in targeted therapy, with tyrosine kinase inhibitors (TKIs) revolutionizing patient outcomes. This progress has extended to the management of pregnancy in women with CML, a complex scenario requiring a balance between disease control and fetal safety. Because TKIs are contraindicated during the first trimester due to their teratogenic potential, treatment must be stopped as soon as pregnancy is confirmed, necessitating careful preconception planning and alternative management strategies. This article uses illustrative clinical cases to explore key aspects of CML pregnancy management, including the timing of TKI discontinuation, the feasibility of treatment-free remission, and the role of alternative therapies such as interferon alfa. Additionally, we discuss the challenges of restarting treatment during pregnancy, the TKI selection in subsequent trimesters, and postpartum disease management, including breastfeeding considerations. Through the analysis of real-world cases, we provide insights into the evolving landscape of CML and pregnancy, offering practical guidance on optimizing maternal and fetal outcomes in this unique setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026513","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:59:46Z","timestamp":1754337586000},"page":"347-356","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["How I manage chronic myeloid leukemia during pregnancy"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6491","authenticated-orcid":false,"given":"Elisabetta","family":"Abruzzese","sequence":"first","affiliation":[{"name":"1Division of Hematology, Sant'Eugenio Hospital, Tor Vergata University, Azienda Sanitaria Locale Roma2, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-1789","authenticated-orcid":false,"given":"Ekaterina","family":"Chelysheva","sequence":"additional","affiliation":[{"name":"2Clinical and Diagnostic Department of Hematology, National Medical Hematology Research Center, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2026012211221255400_bib1","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3390\/jcm9061709","article-title":"Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives","volume":"9","author":"Russo","year":"2020","journal-title":"J Clin Med"},{"issue":"7","key":"2026012211221255400_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib [published correction appears in J Natl Cancer Inst. 2016;108(9):djw211]","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"2026012211221255400_bib3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026012211221255400_bib4","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026012211221255400_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.13192","article-title":"Back to the future: treatment-free remission and pregnancy in chronic myeloid leukemia","volume":"102","author":"Abruzzese","year":"2019","journal-title":"Eur J Haematol"},{"key":"2026012211221255400_bib6","doi-asserted-by":"crossref","first-page":"739171","DOI":"10.3389\/fonc.2021.739171","article-title":"Prognostic factors for overall survival in chronic myeloid leukemia patients: a multicentric cohort study by the Italian CML GIMEMA network","volume":"11","author":"Specchia","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2026012211221255400_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13104-024-06910-9","article-title":"Late presentation of chronic myeloid leukaemia patients in a low-income country: the prognostic implications and impact on treatment outcome","volume":"17","author":"Nelson","year":"2024","journal-title":"BMC Res Notes"},{"issue":"1","key":"2026012211221255400_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-024-01930-8","article-title":"Management of CML and pregnancy in low-and middle-income countries","volume":"41","author":"Malhotra","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"2026012211221255400_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10428194.2016.1201571","article-title":"Pregnancy: part of life in chronic myelogenous leukemia","volume":"58","author":"Law","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026012211221255400_bib10","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7","article-title":"Hydroxyurea therapy in chronic myelogenous leukemia","volume":"29","author":"Kennedy","year":"1972","journal-title":"Cancer"},{"issue":"11","key":"2026012211221255400_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/genes7110099","article-title":"The cell killing mechanisms of hydroxyurea","volume":"7","author":"Singh","year":"2016","journal-title":"Genes (Basel)"},{"issue":"5","key":"2026012211221255400_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/phar.2793","article-title":"Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: current evidence and knowledge gaps","volume":"43","author":"Dong","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2026012211221255400_bib13","first-page":"62","article-title":"Experimental therapy of sickle cell disease. use of hydroxyurea","volume":"16","author":"Charache","year":"1994","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"1","key":"2026012211221255400_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/hematology.2023000497","article-title":"Managing pregnancy in patients with sickle cell disease from a transfusion perspective","volume":"2023","author":"Habibi","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"2026012211221255400_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/bjh.19491","article-title":"Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy","volume":"205","author":"Robertson","year":"2024","journal-title":"Br J Haematol"},{"issue":"suppl 2","key":"2026012211221255400_bib16","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2026012211221255400_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ajh.23593","article-title":"Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon-based therapy moving from interferon to imatinib era","volume":"89","author":"Malagola","year":"2014","journal-title":"Am J Hematol"},{"key":"2026012211221255400_bib18","doi-asserted-by":"crossref","first-page":"20406207241229588","DOI":"10.1177\/20406207241229588","article-title":"Interferons in the treatment of myeloproliferative neoplasms","volume":"15","author":"Vachhani","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2026012211221255400_bib19","doi-asserted-by":"crossref","first-page":"e35611","DOI":"10.1002\/cncr.35611","article-title":"Preg-CML\/Japan study investigators. outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors","volume":"131","author":"Kondo","year":"2025","journal-title":"Cancer"},{"issue":"3","key":"2026012211221255400_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.reprotox.2011.11.003","article-title":"A systematic review of the fetal safety of interferon alpha","volume":"33","author":"Yazdani Brojeni","year":"2012","journal-title":"Reprod Toxicol"},{"issue":"4","key":"2026012211221255400_bib21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2026012211221255400_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2026012211221255400_bib23","doi-asserted-by":"crossref","first-page":"e2014028","DOI":"10.4084\/mjhid.2014.028","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Abruzzese","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"10","key":"2026012211221255400_bib24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2026012211221255400_bib25","doi-asserted-by":"crossref","first-page":"2040620720966120","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"2026012211221255400_bib26","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","article-title":"The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia","volume":"60","author":"Lasica","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026012211221255400_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ejh.13215","article-title":"Risks and challenges of CML management during pregnancy: looking for a balanced decision","volume":"102","author":"Chelysheva","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026012211221255400_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.leukres.2014.10.002","article-title":"Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre","volume":"39","author":"Alizadeh","year":"2015","journal-title":"Leuk Res"},{"issue":"9","key":"2026012211221255400_bib29","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","article-title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","volume":"55","author":"Iqbal","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026012211221255400_bib30","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3816\/CLM.2009.n.064","article-title":"Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature","volume":"9","author":"Cole","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"2026012211221255400_bib31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-024-02183-0","article-title":"Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry","volume":"38","author":"Chelysheva","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2026012211221255400_bib32","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2026012211221255400_bib33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/10428194.2017.1347929","article-title":"Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment","volume":"59","author":"Chelysheva","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026012211221255400_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"issue":"7","key":"2026012211221255400_bib35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/jcm11071801","article-title":"Chronic myeloid leukemia and pregnancy: when dreams meet reality. state of the art, management and outcome of 41 cases, nilotinib placental transfer","volume":"11","author":"Abruzzese","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2026012211221255400_bib36","doi-asserted-by":"crossref","first-page":"e2015020","DOI":"10.4084\/mjhid.2015.020","article-title":"Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib: a case report and a review","volume":"7","author":"Santorsola","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"2026012211221255400_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1078155217692399","article-title":"Experience with dasatinib and nilotinib use in pregnancy","volume":"24","author":"Barkoulas","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"2026012211221255400_bib38","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"issue":"7","key":"2026012211221255400_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","article-title":"A dramatic fetal outcome following transplacental transfer of dasatinib","volume":"23","author":"Berveiller","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"2","key":"2026012211221255400_bib40","doi-asserted-by":"crossref","first-page":"IJH26","DOI":"10.2217\/ijh-2020-0004","article-title":"Pregnancy outcomes in patients treated with bosutinib","volume":"9","author":"Cortes","year":"2020","journal-title":"Int J Hematol Oncol"},{"issue":"suppl 1","key":"2026012211221255400_bib41","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2024-200186","article-title":"The impact of ponatinib on pregnancy outcomes [abstract]","volume":"144","author":"Abruzzese","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026012211221255400_bib42","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00277-025-06238-9","article-title":"Twin pregnancy during treatment with asciminib for chronic myeloid leukemia - a case report","volume":"104","author":"Gutierrez de Moraes Pereira","year":"2025","journal-title":"Ann Hematol"},{"issue":"8","key":"2026012211221255400_bib43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","article-title":"Management of pregnant chronic myeloid leukemia patients","volume":"9","author":"Abruzzese","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2026012211221255400_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0035-1556745","article-title":"Identifying human teratogens: an update","volume":"4","author":"Alwan","year":"2015","journal-title":"J Pediatr Genet"},{"issue":"8","key":"2026012211221255400_bib45","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-023-05280-9","article-title":"Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution","volume":"102","author":"R","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"2026012211221255400_bib46","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/10428194.2020.1849672","article-title":"Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience","volume":"62","author":"Assi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026012211221255400_bib47","volume-title":"StatPearls","author":"Mathew","year":"2025"},{"issue":"11","key":"2026012211221255400_bib48","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/ijc.27560","article-title":"Hematological malignancies and pregnancy: treat or no treat during first trimester","volume":"131","author":"Avil\u00e9s","year":"2012","journal-title":"Int J Cancer"},{"key":"2026012211221255400_bib49","doi-asserted-by":"crossref","first-page":"e100037","DOI":"10.1200\/EDBK_100037","article-title":"Patient-centered care in the management of cancer during pregnancy","volume":"43","author":"Sorouri","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"2026012211221255400_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11095-017-2286-0","article-title":"The placental barrier: the gate and the fate in drug distribution","volume":"35","author":"Tetro","year":"2018","journal-title":"Pharm Res"},{"issue":"4","key":"2026012211221255400_bib51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ajh.2830360404","article-title":"Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children","volume":"36","author":"Avil\u00e9s","year":"1991","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2026012211221255400_bib52","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood-2023-188305","article-title":"On the children side. overview of 194 outcomes from Gimema Registry of Conception\/Pregnancy in chronic myeloid leukemia (CML) [abstract]","volume":"142","author":"Abruzzese","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"2026012211221255400_bib53","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"2026012211221255400_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2023.11.011","article-title":"SOHO state of the art updates and next questions: chronic myeloid leukemia and pregnancy: \"Per Aspera Ad Astra\"","volume":"24","author":"Abruzzese","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026012211221255400_bib55","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026012211221255400_bib56","article-title":"The combination of ponatinib and alpha-interferon can improve outcome of resistant chronic myeloid leukemia patients","volume":"3","author":"Barate","year":"2020","journal-title":"Clin Oncol Case Rep"},{"key":"2026012211221255400_bib57","first-page":"5518727","article-title":"The combination of interferon-alpha and ponatinib enables faster and deeper molecular responses in patient with de novo blast crisis of CML: interferon-alpha may return as a CML treatment","volume":"2021","author":"Hayashi","year":"2021","journal-title":"Case Rep Hematol"},{"key":"2026012211221255400_bib58","doi-asserted-by":"crossref","first-page":"643382","DOI":"10.3389\/fonc.2021.643382","article-title":"Combination therapies in chronic myeloid leukemia for potential treatment-free remission: focus on leukemia stem cells and immune modulation","volume":"11","author":"Mu","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"2026012211221255400_bib59","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"2026012211221255400_bib60","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","article-title":"Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"41","author":"Garc\u00eda-Ferrer","year":"2019","journal-title":"Clin Ther"},{"issue":"1","key":"2026012211221255400_bib61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-024-01603-z","article-title":"Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia","volume":"17","author":"Zu","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026012211221255400_bib62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/17474086.2023.2201429","article-title":"Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations","volume":"16","author":"Robertson","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"suppl 1","key":"2026012211221255400_bib63","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1182\/blood-2023-182220","article-title":"International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission in patients with chronic myeloid leukemia (SUSTRENIM trial): analysis of the eligibility to treatment discontinuation [abstract]","volume":"142","author":"Pane","year":"2023","journal-title":"Blood"},{"key":"2026012211221255400_bib64","unstructured":"Nilotinib. Prescribing information. U.S. Food and Drug Administration. 2010. Accessed 8 August 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf."},{"issue":"5","key":"2026012211221255400_bib65","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026012211221255400_bib66","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"EURO-SKI investigators. discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026012211221255400_bib67","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2026012211221255400_bib68","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1158\/1078-0432.CCR-24-0826","article-title":"Perspectives on drug development for the treatment of chronic myeloid leukemia in pregnant patients and patients who are breastfeeding","volume":"30","author":"Cortes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026012211221255400_bib69","doi-asserted-by":"crossref","first-page":"e2018027","DOI":"10.4084\/mjhid.2018.027","article-title":"Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review","volume":"10","author":"Chelysheva","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"2026012211221255400_bib70","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/1078155220948942","article-title":"Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy","volume":"27","author":"Terao","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"2026012211221255400_bib71","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2006-10-051391","article-title":"Imatinib concentrations in human milk","volume":"109","author":"Gambacorti-Passerini","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2026012211221255400_bib72","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1159\/000510440","article-title":"RT-qPCR versus digital PCR: how do they impact differently on clinical management of chronic myeloid leukemia patients?","volume":"13","author":"Zanaglio","year":"2020","journal-title":"Case Rep Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/4\/347\/2497671\/blood_bld-2024-026513-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/4\/347\/2497671\/blood_bld-2024-026513-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:22:27Z","timestamp":1769098947000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/4\/347\/546477\/How-I-manage-chronic-myeloid-leukemia-during"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026513","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,22]]},"published":{"date-parts":[[2026,1,22]]}}}